A Study of Baricitinib (LY3009104) in Participants With COVID-19

NCT04421027 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1525

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company